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Sleeping sickness in Uganda: a thin line between two fatal
diseases
Kim Picozzi, Eric M Fèvre, Martin Odiit, Mark Carrington, Mark C Eisler, Ian Maudlin,
Susan C Welburn
Abstract
Objective To determine, through the use of molecular
diagnostic tools, whether the two species of parasite
that cause human African trypanosomiasis have
become sympatric.
Design Blood sampling of all available patients
between June 2001 and June 2005 in central Uganda
and between July and September 2003 in northwest
Uganda and analysis of subcounty sleeping sickness
records in Uganda between 1985 and 2005.
Setting Sleeping sickness treatment centres in central
and northwest Uganda and in south Sudan.
Participants Patients presenting at the treatment
centres and diagnosed as having sleeping sickness.
Main outcome measure Classification of parasites
from patients from each disease focus as either
Trypanosoma brucei rhodesiense (acute form) or T b
gambiense (chronic form).
Results Blood from 231 patients with sleeping
sickness in central Uganda and from 91 patients with
sleeping sickness in northwest Uganda and south
Sudan were screened for T b rhodesiense (detection of
SRA gene) and T b gambiense (detection of TgsGP
gene). All samples from central Uganda were
classified as T b rhodesiense, and all samples from
northwest Uganda and south Sudan were identified as
T b gambiense.
Conclusions The two focuses of human African
trypanosomiasis remain discrete, but the area of
Uganda affected by the acute form of human sleeping
sickness has increased 2.5-fold since 1985, spreading
to three new districts within the past five years
through movement of infected livestock. Without
preventive action targeted at the livestock reservoir of
this zoonotic disease, it is likely that the two disease
focuses will converge. This will have a major impact
on diagnosis and treatment of this neglected disease.
Real time monitoring is recommended, using
molecular diagnostic tools (at a regional surveillance
centre, for example) targeted at both livestock and
human patients.
Introduction
Human African trypanosomiasis, or sleeping sickness,
is responsible for an estimated 100 000 deaths every
year.1 Two pathogens are involved: Trypanosoma brucei
rhodesiense, which causes an acute form of disease, and
T b gambiense, the chronic form. T b rhodesiense is found
in east Africa, and T b gambiense is present in central
and west Africa.2 Uganda represents a region of poten-
tial overlap, with the two focuses expanding towards
each other.3–7
Sleeping sickness was first recognised in southeast
Uganda in 1898 and in the north west of the country in
1902.8 9 Refugee movements have spread T b gambiense
to form a contiguous focus with south Sudan,10–12 rais-
ing the possibility that refugees may carry T b gambiense
into areas endemic for T b rhodesiense.3
Animals were implicated in the transmission of T b
rhodesiense disease during the 1940s epidemic in
Busoga, southeast Uganda.13 The disease re-emerged
in Busoga between 1976 and 1983, when 19 974
patients had the disease diagnosed.14 An outbreak of T
b rhodesiense in Tororo district to the east of the Busoga
focus in 1988 was brought under control by 1995 but
not before 1180 cases had presented. Cattle restocking
has been implicated in the latest outbreak of T b rhode-
siense disease in 2000,15 in which 18% of cattle were
found to be carrying the human pathogen.16 The dis-
ease has since spread to two adjacent districts17; the T
b rhodesiense and T b gambiense focuses are predicted to
merge, complicating diagnosis and treatment.1 18
Microscopy of blood, lymph, or cerebrospinal fluid
informs treatment of T b rhodesiense. T b gambiense may
not be evident by microscopy, and diagnosis is based
on the card agglutination test for trypanosomiasis,19
which is ineffective for diagnosis of T b rhodesiense.
Drugs for the treatment of early stage disease differ20:
pentamidine, the first line drug for T b gambiense, is not
effective against early stage T b rhodesiense,21 which is
treated with suramin. Late stage cases of both diseases
are treated with melarsoprol. The number of
treatment failures of late stage T b gambiense is increas-
ing; eflornithine is used in these cases but is not effec-
tive against late stage T b rhodesiense.1 Overlap in the
distribution of these parasites would complicate diag-
nosis and result in inappropriate treatment for
critically ill patients.
We used molecular tools to examine the current
distribution of the two parasite species in Uganda. Spe-
cifically, we observed the historical spread of disease in
terms of land area affected and population at risk and
identified sleeping sickness parasites from the two
focuses.
Methods
Sleeping sickness and geographical area
Disease records for sleeping sickness across Uganda
came from the Co-ordinating Centre for Trypano-
somiasis in Uganda and from sleeping sickness
treatment centres in affected regions. We obtained dig-
ital data for Uganda22 from the geographical informa-
tion system, ArcView 3.2 (Redlands, CA, USA) to
determine the size of geographical areas affected
through time. The administrative units shown on the
map (figure) are districts, the highest administrative
unit in Uganda. We determined the distribution of the
An appendix is on bmj.com
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disease at the level of the subcounty (a lower unit). We
calculated the area of each region at risk from the total
land area of the relevant administrative (district level)
units and determined the population at risk from the
2002 national population and housing census.23
Clinical samples
In southeast Uganda we obtained blood samples from
231 self reporting patients with sleeping sickness from
Soroti, Kaberamaido, and Lira districts who attended
Serere Health Centre between June 2001 and June
2005 (Soroti: 2001 n = 10, 2002 n = 46, 2003 n = 69,
2004 n = 30, and 2005 n = 55; Kaberamaido: 2004
n = 15, 2005 n = 4; Lira 2004 n = 1, 2005 n = 1). We
examined the samples to characterise the trypano-
some parasites present (table 1).
In northwest Uganda and south Sudan we
examined blood samples from 91 patients from the
West Nile/south Sudan focus to characterise the para-
sites present in human blood. These comprised
samples from 27 patients attending Omugo Health
Centre, Arua District (West Nile region) and from 64
patients from three health centres in south Sudan (Kiri
n = 21, Ibba n = 12, Tambura n = 31) between July and
September 2003 (table 1). We also collected samples
from 32 pyrexic patients at Akuem Bahr el Ghazal,
Sudan, outside the sleeping sickness focus, for use as
negative control samples for both T b rhodesiense and T
b gambiense (table 1).
We included all patients who presented for
treatment during the study and were diagnosed as hav-
ing sleeping sickness by clinic staff. The molecular
tools used in this study were applied post hoc—the
diagnosis of sleeping sickness was made in the relevant
clinics according to standard protocols.
Polymerase chain reaction analysis
Patients parasitologically positive for sleeping sickness
were asked to provide a finger prick sample of blood,
which was applied to a DNA binding matrix (FTA card,
Whatman). The local health services obtained consent
from patients, and agreement or otherwise did not
compromise their access to treatment. We prepared
FTA cards containing blood samples from sleeping
sickness patients for polymerase chain reaction (PCR)
as previously described.25 Full details of the PCR meth-
ods are provided in the appendix on bmj.com. Briefly,
we firstly screened samples from all areas for the pres-
ence of human DNA (using human cytoskeletal
gamma actin—HCGA), to confirm that the sample
contained suitable DNA for PCR amplification. We
screened all samples with generic Trypanozoon primers
to identify the presence of T brucei sl DNA.26 We
screened all Trypanozoon positive samples for T b gam-
biense (with primers for TgsGP27 28) and T b rhodesiense
(with primers for the human serum associated gene
SRA16 29). We separated PCR products by agarose
(1.5%) electrophoresis containing ethidium bromide
(0.2 g/ml) and visualised them on an ultraviolet tran-
silluminator.
Results
Since the mid-1980s, the area of Uganda affected by T
b rhodesiense sleeping sickness has increased by a factor
of 2.5, from 13 820 km2 to 34 843 km2, and the popu-
lation at risk from T b rhodesiense has doubled (table 2).
Before 1985, sleeping sickness in east Uganda was
restricted to districts clustered around the north shore
of Lake Victoria and the source of the Nile (the tradi-
tional Busoga focus). During an epidemic that started
in the late 1980s the disease spread eastwards into
Tororo and Busia districts, with sporadic cases in Pal-
lisa and Mbale districts on the Uganda-Kenya border.
This epidemic in Tororo district was brought under
control in the mid-1990s. However, from 1998
onwards, cases of sleeping sickness were detected in
Soroti district, much further to the north; the spread
of this new epidemic area was attributed to the move-
ment of the reservoir host (domestic cattle) as a result
of restocking activities in the region. Control activities
that sought to contain this epidemic were largely
Sequential maps of areas of Uganda affected by sleeping sickness. T b gambiense (in orange)
occurs in south Sudan and northwest Uganda, where substantial human population
movements have occurred as a result of civil instability. T b rhodesiense (in red) has been
spreading since the mid-1980s, and its transmission is now occurring within 150 km of the T
b gambiense active focus. The tsetse belt for Glossina fuscipes fuscipes extends right across
the region24
Table 1 Molecular analysis of samples isolated from patients
with confirmed sleeping sickness
Result of gene screen
Location
No of samples
screened
HCGA
positive*
TgsGP
positive†
SRA
positive‡
T b rhodesiense focus
Soroti district 210 210 0 210
Kaberamaido district 19 19 0 19
Lira district 2 2 0 2
Total 231 231 0 231
T b gambiense focus
Arua district, West Nile 27 27 27 0
Kiri, south Sudan 21 21 21 0
Tambura, south Sudan 31 31 31 0
Ibba, south Sudan 12 12 12 0
Total 91 91 91 0
Control
Akuem Bahr el Ghazal§ 32 32 0 0
*Human DNA present.
† T b gambiense DNA present.
‡T b rhodesiense DNA present.
§Region in Sudan unaffected by either form of human sleeping sickness.
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unsuccessful,15 30 and the disease, having become
established in Soroti district, has spread further still to
Kaberamaido district and more recently to the south-
ern edge of Lira district.17 At the same time,
population movements as a result of civil instability on
the Sudanese border resulted in expansion of the T b
gambiense focus. The affected districts in the two
disease focuses are now approximately 150 km apart
(fig).
We positively identified T b gambiense alone in
blood from all 91 patients with sleeping sickness from
the T b gambiense focus, which included patients
presenting in Arua district (West Nile region), north
Uganda, and from health centres in south Sudan (table
1). None of these samples from this sleeping sickness
focus was amplified by the gene marker SRA specific
for T b rhodesiense, confirming that all patients
examined were infected with T b gambiense parasites. Of
the 231 samples obtained from the T b rhodesiense
sleeping sickness outbreak in east Uganda between
2001 and 2005, all amplified the SRA gene for T b
rhodesiense, showing that all these patients, presenting
from Soroti, Kaberamaido, and Lira, were infected with
T b rhodesiense and confirming SRA as a diagnostic
marker for T b rhodesiense sleeping sickness in East
Africa.16 We saw no amplification in any sample from
Soroti, Kaberamaido, or Lira with TgsGP, confirming
that this gene specific for T b gambiense is not present in
people presenting with sleeping sickness in this region
(table 1).
The results presented here suggest that the
parasites circulating in these two disease focuses
remain discrete and confirm that the disease outbreaks
in Kaberamido and Lira are attributable to T b
rhodesiense (acute form of sleeping sickness), confirm-
ing the recent expansion of the T b rhodesiense focus.
None of the 32 samples from pyrexic patients from
Akuem Bahr el Ghazal in Sudan, outside the sleeping
sickness focuses, that were HCGA positive for human
DNA were infected with T brucei sl.
Discussion
Risk of overlap
Control activities aimed at containing T b rhodesiense in
east Uganda have been largely ineffectual.15 17 30 Civil
instability in the region and a lack of control measures
to contain the spread of disease (such as targeting the
animal reservoir by restricting through cattle move-
ments) have resulted in cases of sleeping sickness
occurring further and further northwards, closer to the
T b gambiense endemic area.
The T b gambiense sleeping sickness focus in north-
west Uganda seems to be relatively stable, but the long
asymptomatic stage associated with this disease means
that, without active surveillance of the human
reservoir population, this parasite could spread with
movements of displaced peoples in the region. In
south Sudan, the absence of disease control activities
for eight years after civil disturbance saw the
expansion of that sleeping sickness focus and some
extremely high disease prevalences (for example, 29%
at Ibbe, Marindi County10).
We have shown, using molecular tools, that the
cases of sleeping sickness in Kaberamaido and Lira
districts of Uganda are indeed due to T b rhodesiense.
Although a real risk of overlap with the T b gambiense
sleeping sickness focus remains, we found no evidence
to indicate that the two active disease focuses have yet
converged—that is, there is no T b rhodesiense within
the T b gambiense sleeping sickness focus or vice versa.
However, the area currently at risk from T b rhodesiense
does now overlap with a region affected by a T b gam-
biense outbreak in 1957.31 The active T b rhodesiense
disease focus is now only 150 km from areas currently
affected by T b gambiense in the north west of
Uganda.
The risk of sleeping sickness spreading by means
of the livestock reservoir host continues to be a public
health challenge. If infected cattle continue to be
traded northwards in the absence of control measures
then overlap of the two disease focuses will inevitably
occur. If and when overlap does occur, a rapid
response including revision of established diagnostic
and treatment protocols will be needed to minimise its
impact. Such a surveillance programme may be
difficult to sustain owing to the unstable nature
of the civil situation in this part of the country.28
Currently, livestock for sale in Uganda are required to
be treated at their point of origin or before sale; this
forms part of the national policy for trypanosomiasis
control, although it has been difficult to implement at
local level.30 Given the high cost of treating patients
and implementing active screening programmes in
new regions with limited human health resources,
strengthening this policy and encouraging its
enforcement by district authorities would seem
appropriate.
Economic analysis suggests that the financial ben-
efits of treating the animal reservoir for T b rhodesiense
sleeping sickness would more than cover the costs of
treatment and may even result in a negative cost per
disability adjusted life year averted. Treating cattle
increases income from livestock, as the trypanocidal
drugs used to clear infection are effective against the
trypanosomes that are pathogenic to cattle as well as
zoonotic T b rhodesiense. Lowering the incidence of
sleeping sickness by treating the animal reservoir will
reduce future costs of treating human patients.32 A
transsectoral assessment of costs and benefits for con-
trol of zoonotic T b rhodesiense, as has been done for
control of brucellosis, would seem appropriate.33
Sleeping sickness tends to affect the poorest and most
disenfranchised rural communities with the least
access to health care. Public health messaging and
extension services are urgently needed to improve
knowledge and reporting of these diseases.
Table 2 Proportional increase in area affected by T b
rhodesiense sleeping sickness in southeast Uganda, 1985-2005
Year Area affected (km2)
Proportional increase
since 1985
1985 13 820 1.00
1995 18 420 1.33
2000 26 019 1.88
2005 34 843 2.52
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Recommendations
Surveillance activities should be put in to place to
monitor the situation, so that any overlap in disease
distribution can be detected at the earliest opportunity.
As the parasites involved in T b gambiense and T b
rhodesiense sleeping sickness are morphologically iden-
tical, such monitoring will inevitably require screening
of blood samples and differentiation of the parasites
with the molecular methods described here. Although
these tools are not yet available at the bedside or pen-
side, the technologies described here are applicable to
a suitably equipped in-country regional laboratory tar-
geted at both livestock and human patients at the lead-
ing edge of the sleeping sickness focuses.17 26 29 The
continent-wide importance of these two parasite
species overlapping is such that a properly equipped
screening laboratory and staff training should be set up
as a matter of urgency. This might take the form of an
internationally funded and locally managed facility
under the supervision of the relevant authorities in
Uganda. Given the economic impact of trypanosomia-
sis on both the livestock and human health sectors,34
this would be a cost effective proposal for management
of this neglected zoonotic disease.
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What is already known on this topic
Two pathogens can cause sleeping sickness:
Trypanosoma brucei rhodesiense, found in east Africa,
and T b gambiense, found in central and west Africa
Uganda represents a region of potential overlap
between the two focuses
What this study adds
The two sleeping sickness focuses in Uganda are
discrete and have not yet overlapped
They are, however, steadily converging and are
now only 150 km apart
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